True North invests ₹536 crore in Biocon arm
The private equity firm’s investment values Biocon Biologics at about $3 billion on a pre-money equity basis.
biocon
January 2020
October 2019
July 2019
January 2019
November 2018
September 2018
April 2018
July 2017
Biocon’s biologics portfolio comes into its own
Bengaluru-based Biocon’s portfolio of biologic drugs has grown rapidly in the last five years and the company wants it to be a $1 billion business by 2022.
Good blueprint, but gaps remain: India Inc.
Focus on infra, housing, financial services, labour reforms welcome; but concerns remain on corporate tax, ability to meet disinvestment target.
Interim Budget 2019: What Kiran Mazumdar-Shaw expects
Here’s what the Biocon MD and chairperson expects from the interim Budget 2019.
Kiran Mazumdar-Shaw: Grit is her secret formula
Overcoming years of criticism and gender bias, Mazumdar-Shaw has proven naysayers wrong by positioning Biocon as an Indian pioneer in the lucrative biologic drugs market.
Inside the issue: Most Powerful Women in business
Here’s a sneak peek into the annual list, and more from the issue.
India-U.S. are natural synergistic partners: Kiran MazumdarShaw
Biocon CMD Kiran Mazumdar Shaw speaks to Fortune India on the sidelines of the USIBC India Ideas Summit; says U.S. and India are natural synergistic partners.
Biocon’s net profit up marginally
Its net profit rose by 2% to Rs 130 crore from Rs 127 crore a year ago, representing a net profit margin of 11%.
Is Biocon undervalued?
The inability of analysts to fully understand biotech companies is keeping the value of Kiran Mazumdar-Shaw’s company down.
